IND Approval
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
Precigen ActoBio
PR-M09-19-NI-006Sep 04, 2019
Diabetes
ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes
Precigen ActoBio
PR-M10-18-NI-105Oct 31, 2018